Jun 22, 2020
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
Jun 17, 2020
Kangpu to Present Two Posters at the 2020 American Association for Cancer Research (AACR) Annual Meeting
May 15, 2020
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting
Apr 06, 2020
Applied Biology to Launch COVID-19 Drug Discovery Platform based on Breakthrough Discovery Made in Collaboration with Brown University Researchers
Mar 31, 2020
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
Feb 27, 2020
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
Feb 10, 2020
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
Nov 04, 2019
Okayama University Research: Synthetic Compound Provides Fast Screening For Potential Drugs
Oct 18, 2019
ESSA Announces Changes to its Board of Directors
Sep 28, 2019
ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress
Aug 14, 2019
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019
Jul 15, 2019
ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer
Jul 08, 2019
ESSA Provides Update on Court Hearing
May 04, 2019
Preclinical Data Highlighting Therapeutic Potential of EPI-7386 Presented at 2019 American Urological Association Annual Meeting
Apr 25, 2019
ESSA Pharma to Attend Bloom Burton & Co. Healthcare Investor Conference 2019
Apr 17, 2019
ESSA Pharma Announces Abstract Presentation at the 2019 American Urological Association Annual Meeting
Apr 12, 2019
ESSA Pharma Grants Stock Options
Mar 18, 2019
ESSA Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference
Mar 14, 2019
ESSA Pharma to Attend the 31st Annual ROTH Conference
Mar 13, 2019
Large Prospective Trial Validates Detection of AR-V7 Biomarker Using Epic Sciences' Platform to Predict Treatment Outcomes for Patients with Advanced Prostate Cancer